We are live on ! Find out more
VMI

VHCP Management II Portfolio holdings

AUM $379M
1-Year Est. Return 421.62%
This Fund
S&P 500
This Quarter Est. Return
-12.84%
1 Year Est. Return
+421.62%
3 Year Est. Return
+2,333.62%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$152M
AUM Growth
+$30.3M
Cap. Flow
+$63M
Cap. Flow %
41.46%
Top 10 Hldgs %
77.62%
Holding
22
New
7
Increased
1
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$22.6M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$20.8M
3
HRTX icon
Heron Therapeutics
HRTX
+$8.01M
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$5.73M
5
ONC
BeOne Medicines Ltd
ONC
+$3.37M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$353K
2
CTMX icon
CytomX Therapeutics
CTMX
+$350K

Sector Composition

Rank Sector Weight
1 Healthcare 88.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVXS
1
DELISTED
AveXis, Inc. Common Stock
AVXS
$24.5M 16.12%
+1,035,657
New +$22.6M
PDSB icon
2
PDS Biotechnology
PDSB
$41.1M
$17.7M 11.64%
96,679
– –
ASND icon
3
Ascendis Pharma A/S
ASND
$17.1B
$13.4M 8.8%
721,152
– –
BCRX icon
4
BioCryst Pharmaceuticals
BCRX
$2.36B
$13.3M 8.73%
+4,689,435
New +$20.8M
RGNX icon
5
Regenxbio
RGNX
$511M
$11.1M 7.32%
1,030,954
– –
HRTX icon
6
Heron Therapeutics
HRTX
$89.1M
$7.71M 5.07%
+405,901
New +$8.01M
CTMX icon
7
CytomX Therapeutics
CTMX
$788M
$7.43M 4.89%
577,831
-25,200
-4% -$350K
CHRS icon
8
Coherus Oncology
CHRS
$216M
$5.5M 3.62%
259,259
– –
AKTX
9
Akari Therapeutics
AKTX
$19.3M
$5.17M 3.4%
462
– –
SIOX
10
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$4.93M 3.24%
+53,699
New +$5.73M
ARCT icon
11
Arcturus Therapeutics
ARCT
$172M
$4.29M 2.82%
161,500
– –
LPCN icon
12
Lipocine
LPCN
$18.4M
$4.26M 2.8%
24,706
– –
ORKA
13
Oruka Therapeutics
ORKA
$5.59B
$3.74M 2.46%
4,995
– –
ONC
14
BeOne Medicines Ltd
ONC
$32.4B
$3.49M 2.29%
+119,000
New +$3.37M
OCRX
15
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.79M 1.83%
+948,372
New +$2.71M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$2.7M 1.78%
170,312
+28,701
+20% +$510K
STML
17
DELISTED
Stemline Therapeutics, Inc.
STML
$1.47M 0.97%
315,980
– –
ADVM
18
DELISTED
Adverum Biotechnologies
ADVM
$1.45M 0.95%
28,000
– –
LRMR icon
19
Larimar Therapeutics
LRMR
$384M
$945K 0.62%
+11,790
New +$931K
SRRA
20
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$882K 0.58%
3,270
-1,105
-25% -$353K

Similar funds

ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
PI
PHH Investments Addison, Texas $378M AUM 19.74% 1-Year Est. Return
SC
Southside Capital Miami Beach, Florida $382M AUM 30.29% 1-Year Est. Return
FFSOTS
Fiduciary Financial Services of The Southwest Dallas, Texas $382M AUM 25.98% 1-Year Est. Return
PC
Passport Capital San Francisco, California $394M AUM 50.67% 1-Year Est. Return
WC
Whitnell & Co Oak Brook, Illinois $326M AUM 25.97% 1-Year Est. Return
VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
LB
Landmark Bank Columbia, Missouri $444M AUM 30.12% 1-Year Est. Return

VHCP Management II's Q1 2016 Portfolio in Review

As of Q1 2016, VHCP Management II held 22 positions worth $152M, up 25% from $122M the previous quarter. Its ten largest holdings account for 78% of the portfolio.

VHCP Management II deployed $63M of net new capital in Q1 2016, opening 7 new positions and adding to 1 existing holding. Its largest new stake was AveXis, Inc. Common Stock: 1,035,657 shares worth $24.5M.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 85% a quarter earlier.

On the sell side, the largest reduction was Sierra Oncology, Inc. Common Stock, an estimated $353K trimmed.

  • VHCP Management II's largest Q1 2016 buy was AveXis, Inc. Common Stock: 1,035,657 shares worth $24.5M.
  • VHCP Management II added most to Global Blood Therapeutics, Inc. in Q1 2016, an estimated $510K increase.
  • VHCP Management II's biggest Q1 2016 reduction was Sierra Oncology, Inc. Common Stock, cutting an estimated $353K.
  • VHCP Management II's ten largest holdings make up 78% of its $152M portfolio in Q1 2016.
  • VHCP Management II opened 7 new positions and closed 0 in Q1 2016.
  • VHCP Management II's portfolio value rose 25% quarter-over-quarter to $152M.

Based on VHCP Management II's 13F filing for Q1 2016, filed 13 May 2016.